Dr. Sola Morales will discuss about the topic that in 1999, the EU enacted legislation to foster the introduction of new Orphan Medicinal Products (OMP) into the market. To date only partial evaluations of the success of this legislation have been made, so this analysis investigates the outcomes of the OMP legislation from a broader perspective.
Taking part in the XXXVII Jornadas de economia de la salud.
The objective of this workshop was achieving a multistakeholder work table discussing about issues related to drugs pricing, focusing the horizon scanning, access to innovation, current and future role of insurances and private providers.
Dr. Solà-Morales was invited to give a presentation in a plenary session at the 20th National Hospital Congess (Sevilla, dates) on uses of Real World Evidence (RWE).
hitt ha participat a la jornada Lessons Learned: Market Access and Reimbursement organitzada per l’associació d’empreses CataloniaBio i Biocat el 29 de novembre al Parc Científic de Barcelona, on també s’han pogut escoltar i debatre les lliçons apreses d’altres experts consultors i de la indústria del sector.
El próximo jueves 25 de febrero hitt participará en la mesa redonda sobre Acceso al Mercado y Acuerdos Innovadores en España convocada por Insights in Life Sciences (ilS) i CataloniaBio, que tendrá lugar en el Parc Científic de Barcelona y contará con la participación de representantes del Institut Cataàà d’oncología, CatSalut y Almirall.
HITT has recently attended ISPOR’s Meeting and debated on the possibility of achiveing harmonised market entry authorisations or agreements across the EU. Read here the executive summary.